Polydioxanone

Polydioxanone (50% hydroxyapatite loading in PDX scaffold) electrospun scaffolds exhibit superior mineralization potential compared to PLGA/50% HA scaffolds in ionic and revised simulated body fluids^[2].
Polydioxanone (50:50 PDX/elastin scaffold; 7 days) electrospun scaffolds support full thickness migration of human dermal fibroblasts within 7 days, unlike pure PDX scaffolds^[2].
Polydioxanone (0-40% PDX loading in composite scaffolds; 7-21 days)/fibrinogen composite scaffolds support human bladder smooth muscle cell migration, spreading, and layered growth, with higher PDX content promoting cell morphologies closer to native bladder smooth muscle cells over 21 days^[2].
Polydioxanone (varying degrees of grafted PDX chains; to 100% release endpoint) copolymers provide sustained release of Ibuprofen (HY-78131) in pH 7.4 PBS, with slower release rates associated with higher degrees of grafted PDX chains compared to pure chitosan carriers^[2].
Polydioxanone (42-167 mg/mL) solutions in HFP exhibit viscosity ranging from 50 to 2856 cP across concentrations of 42 to 167 mg/mL, with a defined optimal viscosity range for electrospinning^[3].
Dry polydioxanone (42-167 mg/mL) electrospun scaffolds exhibit anisotropic mechanical properties, with higher strength and rigidity in the longitudinal orientation of aligned fibers, and increasing mechanical performance with increasing PDS concentration; hydration of 100 mg/mL scaffolds increases strain at failure without adversely affecting modulus or peak stress^[3].
Polydioxanone (10% Vancomycin (HY-B0671) + 10% Rifampicin (HY-B0272) loading in PDX fibers) electrospun fibers exhibit superior inhibition of osteomyelitis-associated bacterial biofilm growth compared to single-drug loaded and pure PDX fibers^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.